Medicine and Dentistry
Azacitidine
100%
DNA Determination
100%
B-Cell Chronic Lymphocytic Leukemia
100%
Ibrutinib
100%
Morphology
100%
Rectum Cancer
100%
Prospective Cohort Study
100%
Mechanistic Target of Rapamycin
100%
Neoplasm
100%
Richter's Transformation
100%
Liquid Biopsy
75%
Colorectal Cancer
75%
Chronic Myelomonocytic Leukemia
66%
Acute Myeloid Leukemia
66%
Myelodysplastic Syndrome
66%
Tumor Biopsy
50%
Overall Survival
33%
Proportional Hazards Model
33%
Clinical Trial
33%
Biopsy Sample
25%
Minimal Residual Disease
25%
N [bis(1 Aziridinyl)phosphinyl] 4 Iodobenzamide
25%
Tumour Heterogeneity
25%
Disease Assessment
25%
Next Generation Sequencing
25%
Circulating Tumor DNA
25%
Malignant Neoplasm
25%
Mortality Rate
25%
Exome
14%
Gene Expression Profiling
14%
B Lymphocyte Receptor
14%
Mammalian Target of Rapamycin Inhibitor
14%
Recurrence Risk
14%
Case Presentation
14%
Therapy Resistance
14%
Bruton Tyrosine Kinase
14%
Pharmacology, Toxicology and Pharmaceutical Science
Phosphotransferase
100%
Chronic Myeloid Leukemia
100%
Azacitidine
100%
Prospective Cohort Study
100%
Remission
100%
Cyclooxygenase 2
100%
Transient Receptor Potential Channel M7
33%
Inflammation
22%
Malignant Neoplasm
22%
Chronic Myelomonocytic Leukemia
18%
Myelodysplastic Syndrome
18%
Acute Myeloid Leukemia
18%
Cation Channel
11%
Protein Serine Threonine Kinase
11%
Receptor
11%
Tumor Growth
11%
Leukemia
11%
Clinical Trial
9%
Overall Survival
9%
Nursing and Health Professions
Remission
100%
Prospective Cohort Study
100%
Azacitidine
100%
Acute Myeloid Leukemia
18%
Myelodysplastic Syndrome
18%
Chronic Myelomonocytic Leukemia
18%
Gold Standard
9%
Blood Cell Count
9%
Overall Survival
9%
Proportional Hazards Model
9%
Predictive Value
9%